ArticleEuropean journal of medical research2025
Longitudinal serum total bile acid trajectories and risk of metabolic dysfunction-associated fatty liver disease: a retrospective cohort study.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEvidence from cohort studies on the relationship between metabolic dysfunction-associated fatty liver disease (MAFLD) and longitudinal changes in total bile acid (TBA) remains limited. This study aimed to investigate the association of TBA trajectories with new-onset MAFLD and liver fibrosis.
methodsA total of 3259 participants who underwent at least three health examinations at a hospital in Zhejiang between 2019 and 2023 were included. MAFLD was diagnosed via abdominal ultrasound, and liver fibrosis was assessed using the NAFLD fibrosis score (NFS) and fibrosis-4 score (FIB-4). Logistic regression models were used to analyse the associations between TBA trajectories and the risk of MAFLD and liver fibrosis.
resultsDuring follow-up, 715 participants developed MAFLD. Among them, 15.10% had high NFS status, and 12.17% had high FIB-4 status. Compared with the low-stable TBA trajectory group, the high-stable trajectory group had a significantly higher risk of new-onset MAFLD (adjusted OR = 1.448, 95% CI 1.157-1.812). Subgroup analyses confirmed the robustness of these findings. Multinomial logistic regression revealed that the high-stable trajectory was associated with an increased risk of high NFS (adjusted OR = 2.435, 95% CI 1.568-3.781, P < 0.001) and high FIB-4 (adjusted OR = 3.194, 95% CI 2.006-5.087, P < 0.001).
conclusionsTBA trajectories are significantly associated with the risk of new-onset MAFLD and advanced liver fibrosis, as indicated by high NFS and FIB-4 scores. These findings highlight the potential role of TBA dynamics in MAFLD progression and fibrosis risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.